Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users.

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a 37% reduced risk for dementia and a 19% reduced risk for ischemic stroke ...

"Although there was a signal of lower incidence of dementia with GLP-1 RAs than with DPP4is among adults younger than 75 years, the causal relationship remains unclear." HealthDay News — For older ...

Bariatric metabolic surgery (BMS) offers a survival advantage over glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in adults with obesity and diabetes for ≤ 10 years, which may be explained by ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals. The ...

The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) updated their 2019 clinical practice ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR. (HealthDay News) — For individuals with type 2 diabetes (T2D), ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...